Avanir Pharmaceuticals Inc (AVNR)

Currency in USD
16.960
0.000(0.00%)
Closed·
Showing Avanir historical data. For real-time data please try another search
Day's Range
16.96016.975
52 wk Range
0.00016.975
Key Statistics
Prev. Close
16.96
Open
16.96
Day's Range
16.96-16.975
52 wk Range
0-0
Volume
-
Average Volume (3m)
5.41M
1-Year Change
0%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock

Avanir Pharmaceuticals Inc Company Profile

Avanir Pharmaceuticals, Inc., together with its subsidiaries, engages in acquiring, developing, and commercializing novel therapeutic products for the treatment of central nervous system disorders primarily in the United States. It primarily offers NUEDEXTA, a dual N-methyl-D-aspartate receptor antagonist and sigma-1 agonist for the treatment of pseudobulbar affect; and Docosanol 10% cream, an over-the-counter product for the treatment of cold sores. The company is also involved in Phase II clinical trial of AVP-923 for the treatment of central neuropathic pain in patients with multiple sclerosis, agitation in patients with Alzheimer’s disease, and levodopa-induced-dyskinesia in Parkinson’s disease. In addition, it is developing AVP-786, a Phase II clinical trial product for the treatment of major depressive disorder; and AVP-825, an investigational drug-device combination product consisting of low-dose sumatriptan powder for the acute treatment of migraine. The company has a license agreement with Concert Pharmaceuticals, Inc. to develop and commercialize deuterium-modified dextromethorphan for the potential treatment of neurologic and psychiatric disorders, as well as rights to other deuterium-modified dextromethorphan compounds; and a license agreement with OptiNose AS for the development and commercialization of a novel breath powered intranasal delivery system to treat acute migraine. Avanir Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Aliso Viejo, California. Avanir Pharmaceuticals, Inc. operates as a subsidiary of Otsuka America, Inc.

Industry
-
Sector
-
Employees
484

Earnings

Latest Release
Feb 07, 2019
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

AVNR Income Statement

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.